Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises '23 View
02:43pm, Thursday, 27'th Jul 2023
AbbVie's (ABBV) second-quarter 2023 earnings and sales beat estimates. The company raises its EPS guidance.
Why AbbVie Stock Is Jumping Today
12:13pm, Thursday, 27'th Jul 2023
AbbVie easily beat Wall Street estimates for the second quarter. The company also raised its full-year earnings guidance.
How AbbVie's Humira Still Reigns, Despite New Competition
11:45am, Thursday, 27'th Jul 2023Compared to Estimates, AbbVie (ABBV) Q2 Earnings: A Look at Key Metrics
11:42am, Thursday, 27'th Jul 2023
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to
AbbVie shares climb after quarterly results beat expectations
08:14am, Thursday, 27'th Jul 2023
AbbVie Inc. ABBV, +0.19% shares gained 1.5% premarket on Thursday after the pharmaceutical giant reported stronger-than-expected revenue for the second quarter and raised its full-year guidance. The c
AbbVie raises annual profit forecast as Humira stays strong, new drugs impress
07:42am, Thursday, 27'th Jul 2023
AbbVie on Thursday raised its annual profit forecast after beating analysts' estimates for second-quarter earnings on a lower-than-expected fall in sales of blockbuster arthritis drug Humira and stron
AbbVie may see less pain from Humira sales decline as rival lags
12:07pm, Wednesday, 26'th Jul 2023
AbbVie Inc is likely to beat Wall Street sales estimates for Humira in the second quarter as the only copycat in the U.S. market for the blockbuster arthritis drug struggled to gain traction.
3 Stocks to Buy While They Are on Sale
05:51am, Wednesday, 26'th Jul 2023
AbbVie's Humira headwinds should only be temporary. Alibaba could be poised for stronger growth with its planned restructuring.
Will AbbVie's (ABBV) New Drugs Make Up for Low Humira Sales?
12:22pm, Tuesday, 25'th Jul 2023
In its Q2 earnings results, AbbVie's (ABBV) Skyrizi and Rinvoq sales are expected to have made up for the declining Humira sales following the loss of U.S. exclusivity.
AbbVie turns to newer immunology drugs as blockbuster Humira faces lower-cost competition
10:41am, Tuesday, 25'th Jul 2023
As AbbVie Inc. ABBV, -0.63% looks to plug holes in the sales of its mega-blockbuster arthritis drug Humira, newer immunology drugs will be key to the pharmaceutical giant's future growth, analysts say
The 7 Best Dividend Stocks to Protect Your Portfolio From Global Chaos
07:54pm, Monday, 24'th Jul 2023
Although the best dividend stocks for portfolio protection might come off as a rather boring endeavor, at the present juncture, there may be no more relevant idea for investors. Frankly, with the worl
3 Non-Tech Reports to Watch This Week
07:07pm, Monday, 24'th Jul 2023
While many remain focused on tech, there are several other notable quarterly reports scheduled to come this week, including these three.
3 High-Yield Dividend Stocks I Plan on Holding Forever
05:50am, Friday, 21'st Jul 2023
AbbVie is a Dividend King with a long history of innovation. Brookfield Renewable has a clear path to long-term growth.
3 of the Best Dividend Stocks to Buy for Passive Income Growth
04:18pm, Thursday, 20'th Jul 2023
Investors seeking income from dividend stocks should carefully consider the yield offered. While the average yield in the S&P 500 is 1.56%, some stocks offer double or even triple that amount.
7 Fantastic Forever Stocks for Long-Term Lucrative Gains
12:49pm, Thursday, 20'th Jul 2023
Investing is about building a stable long-term portfolio, not just seeking immediate gains. In a mixed economic climate with rising employment figures, savvy investors seek forever stocks.
